Boehringer Ingelheim Pharmaceuticals‘s Cyltezo, a second biosimilar for AbbVie’s Humira, received FDA approval.
AzurRx BioPharma enrolled a sixth patient into its phase IIa trial for MS1819, a treatment for exocrine pancreatic insufficiency associated with chronic pancreatitis.
4D Pharma is preparing to move its irritable bowel syndrome drug, Blautix, into a phase II clinical trial.
More articles on gastroenterology:
Stock market week-in-review for 5 large GI companies — Aug. 21-25
GI center to know: Associated Endoscopy
GI leader to know: Dr. G. Whit James of Associates in Gastroenterology
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
